Amgen Presents at MEDCAC Meeting on ESAs in Chronic Kidney Disease

On Wednesday, January 19, 2011, Amgen presented evidence on the impact of erythropoiesis-stimulating agent (ESA) use on transplanted kidney survival at the Centers for Medicare and Medicaid Services (CMS) Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) Meeting.